[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100537665":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":12,"centralContacts":25,"locations":35,"responsibleParty":218,"collaborators":220,"id":231,"slug":232,"hasResults":233,"nctId":234,"briefTitle":235,"officialTitle":236,"acronym":237,"eligibilityCriteria":238,"healthyVolunteers":233,"sex":239,"minAge":240,"maxAge":12,"enrollmentInfo":241,"targetDuration":12,"studyType":244,"phases":245,"briefSummary":247,"conditions":248,"keywords":12,"overallStatus":38,"whyStopped":12,"lastUpdateSubmitDate":250,"lastUpdatePostDateStruct":251,"startDateStruct":254,"completionDateStruct":256,"leadSponsor":258,"locationsCount":259},{"fullName":5,"class":6},"Imperial College London","OTHER",[8,13],{"label":9,"type":10,"description":11,"interventionNames":12},"Standard care (Control) Arm","NO_INTERVENTION","PSA 3 monthly in year 1 and then 6 monthly with rectal exam annually if clinically indicated. MRI will be carried out at 12 months (if not had one at diagnosis). If a diagnostic MRI was carried out, a 12 month MRI scan will not be required. A biopsy will be required if indicated due to changes in rectal exam or PSA. Follow-up for 5 years.",null,{"label":14,"type":15,"description":16,"interventionNames":17},"Intervention Arm","EXPERIMENTAL","Patients with a visible lesion or medium risk cancer will have PSA 6 monthly and MRI scans annually. As per international PIRADS committee guidance the surveillance MRIs will be biparametric MRI scans which last approximately 15 minutes and exclude gadolinium contrast injection. All other patients will undergo PSA 6 monthly and MRI in years 1, 3 and 5. In all patients, a targeted biopsy will be carried out if the MRI PRECISE score is \\>\u002F=4.",[18],"Diagnostic Test: MRI Scans",[20],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":12},"DIAGNOSTIC_TEST","MRI Scans","The regular use of MRI in active surveillance will lead to greater confidence in active surveillance for patients with low and medium risk prostate cancer. This is because such a strategy is likely to detect cancer progression earlier with fewer invasive biopsies. Those patients randomised to the intervention arm will have additional MRI scans. These will be non-contrast so there is no risk from having repeated 1-2 yearly injections of gadolinium contrast. Patients with contraindications to MRI will not be taking part in the study so will not be exposed to an unnecessary MRI.\n\nPatients with a visible lesion or medium risk cancer will have PSA 6 monthly and MRI annually. All other patients will undergo PSA 6 monthly and MRI in years 1, 3 and 5. In all patients, a targeted biopsy will be carried out if the MRI PRECISE score is \\>\u002F=4.",[14],[26,31],{"name":27,"role":28,"phone":29,"phoneExt":12,"email":30},"Hashim Ahmed","CONTACT","+44 (0)20 7594 1660","hashim.ahmed@imperial.ac.uk",{"name":32,"role":28,"phone":33,"phoneExt":12,"email":34},"Increase Akinyemi","+447731513982","i.akinyemi@imperial.ac.uk",[36,57,73,88,103,117,129,141,156,171,186,203],{"facility":37,"status":38,"city":39,"state":40,"zip":41,"country":42,"countryCode":43,"cosmosGeoPoint":44,"geoPoint":49,"contacts":50},"Heatherwood Hospital","RECRUITING","Ascot","Berkshire","SL5 7GB","United Kingdom","UK",{"type":45,"coordinates":46},"Point",[47,48],-0.6748,51.41082,{"lat":48,"lon":47},[51,54],{"name":52,"role":28,"phone":12,"phoneExt":12,"email":53},"Lauren Barnett","lauren.barnett6@nhs.net",{"name":55,"role":56,"phone":12,"phoneExt":12,"email":12},"Nishant Bedi","PRINCIPAL_INVESTIGATOR",{"facility":58,"status":38,"city":59,"state":60,"zip":61,"country":42,"countryCode":43,"cosmosGeoPoint":62,"geoPoint":66,"contacts":67},"Darent Valley Hospital","Dartford","Kent","DA2 8DA",{"type":45,"coordinates":63},[64,65],0.21423,51.44657,{"lat":65,"lon":64},[68,71],{"name":69,"role":28,"phone":12,"phoneExt":12,"email":70},"Charlotte Kamundi","charlotte.kamundi1@nhs.net",{"name":72,"role":56,"phone":12,"phoneExt":12,"email":12},"Sanjeev Madaan",{"facility":74,"status":38,"city":75,"state":12,"zip":12,"country":42,"countryCode":43,"cosmosGeoPoint":76,"geoPoint":80,"contacts":81},"Bradford Royal Infirmary","Bradford",{"type":45,"coordinates":77},[78,79],-1.75206,53.79391,{"lat":79,"lon":78},[82,86],{"name":83,"role":28,"phone":84,"phoneExt":12,"email":85},"Imran Hamid","07778 954483","imran.hamid@bthft.nhs.uk",{"name":87,"role":56,"phone":12,"phoneExt":12,"email":12},"Rohit Chahal",{"facility":89,"status":38,"city":90,"state":12,"zip":12,"country":42,"countryCode":43,"cosmosGeoPoint":91,"geoPoint":95,"contacts":96},"St Peter's Hospital","Chertsey",{"type":45,"coordinates":92},[93,94],-0.50782,51.38812,{"lat":94,"lon":93},[97,101],{"name":98,"role":28,"phone":99,"phoneExt":12,"email":100},"Keshnie Govender","01932726851","keshnie.govender@nhs.net",{"name":102,"role":56,"phone":12,"phoneExt":12,"email":12},"Nimalan Arumainayagam",{"facility":104,"status":38,"city":105,"state":12,"zip":106,"country":42,"countryCode":43,"cosmosGeoPoint":107,"geoPoint":111,"contacts":112},"Charing Cross Hospital","London","W6 8RF",{"type":45,"coordinates":108},[109,110],-0.12574,51.50853,{"lat":110,"lon":109},[113,116],{"name":114,"role":28,"phone":12,"phoneExt":12,"email":115},"Archana Gopalakrishnan","archana.gopalakrishnan@imperial.ac.uk",{"name":27,"role":56,"phone":12,"phoneExt":12,"email":12},{"facility":118,"status":38,"city":105,"state":12,"zip":12,"country":42,"countryCode":43,"cosmosGeoPoint":119,"geoPoint":121,"contacts":122},"Kings College London",{"type":45,"coordinates":120},[109,110],{"lat":110,"lon":109},[123,127],{"name":124,"role":28,"phone":125,"phoneExt":12,"email":126},"Sahin Emer","0 203 299 6860","sahin.emer@nhs.net",{"name":128,"role":56,"phone":12,"phoneExt":12,"email":12},"Nicholas Raison",{"facility":130,"status":38,"city":105,"state":12,"zip":12,"country":42,"countryCode":43,"cosmosGeoPoint":131,"geoPoint":133,"contacts":134},"West Middlesex Hospital",{"type":45,"coordinates":132},[109,110],{"lat":110,"lon":109},[135,139],{"name":136,"role":28,"phone":137,"phoneExt":12,"email":138},"Metod Oblak","07766064813","metod.oblak@nhs.net",{"name":140,"role":56,"phone":12,"phoneExt":12,"email":12},"Mathias Winkler",{"facility":142,"status":38,"city":143,"state":12,"zip":12,"country":42,"countryCode":43,"cosmosGeoPoint":144,"geoPoint":148,"contacts":149},"Freeman Hospital","Newcastle upon Tyne",{"type":45,"coordinates":145},[146,147],-1.61396,54.97328,{"lat":147,"lon":146},[150,154],{"name":151,"role":28,"phone":152,"phoneExt":12,"email":153},"Jade Whitehead","0191 2137322","jade.whitehead2@nhs.net",{"name":155,"role":56,"phone":12,"phoneExt":12,"email":12},"Rajan Veeratterapillay",{"facility":157,"status":38,"city":158,"state":12,"zip":12,"country":42,"countryCode":43,"cosmosGeoPoint":159,"geoPoint":163,"contacts":164},"Glan Clywd Hospital","Rhyl",{"type":45,"coordinates":160},[161,162],-3.49228,53.31929,{"lat":162,"lon":161},[165,169],{"name":166,"role":28,"phone":167,"phoneExt":12,"email":168},"Sharon Harland","+44 3000 844543","Sharon.Harland@wales.nhs.uk",{"name":170,"role":56,"phone":12,"phoneExt":12,"email":12},"Kingsley Ekwueme",{"facility":172,"status":38,"city":173,"state":12,"zip":12,"country":42,"countryCode":43,"cosmosGeoPoint":174,"geoPoint":178,"contacts":179},"Northern Lincolnshire and Goole NHS Foundation Trust","Scunthorpe",{"type":45,"coordinates":175},[176,177],-0.65437,53.57905,{"lat":177,"lon":176},[180,184],{"name":181,"role":28,"phone":182,"phoneExt":12,"email":183},"Dorota Potoczna","03033 305867","dorota.potoczna@nhs.net",{"name":185,"role":56,"phone":12,"phoneExt":12,"email":12},"Mark Rogers",{"facility":187,"status":38,"city":188,"state":12,"zip":12,"country":42,"countryCode":43,"cosmosGeoPoint":189,"geoPoint":193,"contacts":194},"Southampton University Hospital","Southampton",{"type":45,"coordinates":190},[191,192],-1.40428,50.90395,{"lat":192,"lon":191},[195,198,201],{"name":196,"role":28,"phone":12,"phoneExt":12,"email":197},"Nikki Carney","Nikki.Carney@uhs.nhs.uk",{"name":199,"role":28,"phone":12,"phoneExt":12,"email":200},"Aneta Zahorska","Aneta.Zahorska@uhs.nhs.uk",{"name":202,"role":56,"phone":12,"phoneExt":12,"email":12},"Tim Dudderidge",{"facility":204,"status":38,"city":205,"state":12,"zip":12,"country":42,"countryCode":43,"cosmosGeoPoint":206,"geoPoint":210,"contacts":211},"North Cumbria","Whitehaven",{"type":45,"coordinates":207},[208,209],-3.58412,54.54897,{"lat":209,"lon":208},[212,216],{"name":213,"role":28,"phone":214,"phoneExt":12,"email":215},"Rachel Mutch","07811714656","Rachel.mutch@ncic.nhs.uk",{"name":217,"role":56,"phone":12,"phoneExt":12,"email":12},"Yannick Yangue",{"type":219,"investigatorFullName":12,"investigatorTitle":12,"investigatorAffiliation":12,"oldNameTitle":12,"oldOrganization":12},"SPONSOR",[221,223,225,227,229],{"name":222,"class":6},"Queen Mary University of London",{"name":224,"class":6},"University of Leeds",{"name":226,"class":6},"University College, London",{"name":228,"class":6},"University of York",{"name":230,"class":6},"University College London Hospitals","100537665","imperial-prostate-9---atlas-approaches-to-long-term-active-surveillance-100537665",false,"NCT06280781","Imperial Prostate 9 - ATLAS (Approaches To Long-Term Active Surveillance)","A Randomised Controlled Trial of Regular MRI Scans Compared to Standard Care in Patients With Prostate Cancer Managed Using Active Surveillance","IP9-ATLAS","Inclusion Criteria:\n\n* Age 18 years or above (no upper limit)\n* Patients with a prostate (either cis-male gender or trans-female gender with no prior androgen deprivation hormone use at all).\n* Diagnostic bi-parametric or multiparametric MRI\n* Diagnostic systematic biopsy +\u002F- targeted biopsy\n* A histological diagnosis of localised prostate cancer\n* Patient chosen active surveillance\n\nExclusion Criteria:\n\n* On active surveillance for greater than 9 months prior to screening date.\n* Contraindication to MRI or gadolinium contrast\n* Previous hip replacement to both hips\n* Contraindication to performing a biopsy guided by a transrectal ultrasound probe","MALE","18 Years",{"count":242,"type":243},1263,"ESTIMATED","INTERVENTIONAL",[246],"NA","The goal of this intervention study is for patients on active surveillance for prostate cancer, to demonstrate that use of regular MRI scans is better able to detect cancer progression over 5 years compared to the current NICE defined strategy.\n\nResearch Question P - In patients who are on active surveillance for low to medium risk prostate cancer, I - is the use of regular MRI scans C - compared to current NICE defined standard of care, O - better at detecting cancer progression with less cost to the NHS (fewer PSA tests, biopsies and clinic visits)?\n\nPatients will be allocated in a 1.1 ratio to either MRI scans or the current NICE defined standard. Randomisation will be blocked (random block size) and stratified by MRI visibility of lesions (3 categories \\[ no visible lesion, diffuse changes, discrete visible lesion\\]), cancer Grade Group (GG1, GG2) and time since diagnosis. This study will not be blinded to patients or physicians.",[249],"Prostate Cancer","2026-03-25",{"date":252,"type":253},"2026-03-30","ACTUAL",{"date":255,"type":253},"2024-05-24",{"date":257,"type":243},"2032-06",{"name":5,"class":6},12]